ANCA Screen with Reflex to ANCA Titers

Overview

  • EPIC Code:
  • IMO5092
  • Soft Test Code:
  • ANCAT
  • Send Out Test Code:
  • 70171
Alternate Names
  • ANCA Scrn, Reflex ANCA Titer
Included Tests

ANCA Screen; Reflex (Atypical P-ANCA Titer; C-ANCA Titer; P-ANCA Titer)


Clinical Significance

Testing for anti-neutrophil cytoplasmic antibodies (P-ANCA and or C-ANCA) has been found to be useful in establishing the diagnosis of suspected vascular diseases (e.g., crescentic glomerulonephritis, microscopic polyarteritis and churg-strauss syndrome), bowel disease (Crohn's Disease, ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis) as well as with other autoimmune diseases (drug-induced lupus, SLE, Felty's Syndrome).
ANCA has classically been divided into C-ANCA and P-ANCA depending on the immunofluorescent pattern observed. More recently the specific antigens responsible for these patterns have been described and isolated. The antigen that gives the C-ANCA pattern is Proteinase-3 (PR-3). Multiple antigens are responsible for P-ANCA pattern, the principle antigen being Myeloperoxidase (MPO).
Patients with bowel disease have been shown to have antibodies that give a P-ANCA or C-ANCA pattern. These antibodies however may not be directed towards MPO. Patients with drug induced lupus, etc, often present with a P-ANCA pattern that is associated with antibodies against MPO.


Specimen Collection & Preparation

Specimen Requirements

1.0 mL Serum from a Red Top Tube in a Plastic Vial

Alternate Specimen

 1.0 mL Serum from a SST Gold Top Tube

TransportAndStorage

7 days Ambient
14 days Refrigerated
30 days Frozen

Collection Instructions

 

Clinical Interpretation

Reference Range:

ANCA Screen Negative
  C-ANCA Titer <1:20
  P-ANCA Titer <1:20
  Atypical P-ANCA Titer <1:20


Test Comments:

If ANCA Screen is positive, then C-ANCA Titer and/or P-ANCA Titer, and/or atypical P-ANCA Titer will be performed at an additional charge (CPT code(s): 86021 for each titer performed)


Methodology:
  • Immunoassay (IA)

Clinical Significance

Testing for anti-neutrophil cytoplasmic antibodies (P-ANCA and or C-ANCA) has been found to be useful in establishing the diagnosis of suspected vascular diseases (e.g., crescentic glomerulonephritis, microscopic polyarteritis and churg-strauss syndrome), bowel disease (Crohn's Disease, ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis) as well as with other autoimmune diseases (drug-induced lupus, SLE, Felty's Syndrome).
ANCA has classically been divided into C-ANCA and P-ANCA depending on the immunofluorescent pattern observed. More recently the specific antigens responsible for these patterns have been described and isolated. The antigen that gives the C-ANCA pattern is Proteinase-3 (PR-3). Multiple antigens are responsible for P-ANCA pattern, the principle antigen being Myeloperoxidase (MPO).
Patients with bowel disease have been shown to have antibodies that give a P-ANCA or C-ANCA pattern. These antibodies however may not be directed towards MPO. Patients with drug induced lupus, etc, often present with a P-ANCA pattern that is associated with antibodies against MPO.


Production Schedule

Sites Performed
  • Quest - Chantilly
Days Performed
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Departments
  • Sendouts - Clinical
Turn Around Time

3 to 5 days


Coding & Compliance

CDM

00918803, 00918800, 00918802, 00918801


CPT Coding

86036, 86037 x3